skip to Main Content

April 6, 2021
TAG EU and UK TB Research and Development Advocacy Consultant
TAG is seeking a consultant to advance strategic policy-advocacy and resource mobilization efforts for TB R&D in the context of EU and UK global development cooperation. The consultant will be responsible for engaging policymakers, investigating legislative opportunities, and executing advocacy strategies in collaboration with TAG to increase TB R&D resources…

April 4, 2021
TAG Comments on NIST’s Proposed Rulemaking Changes
Letter / Comment
TAG submitted comments in response to the National Institute of Standards and Technology’s (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically…

April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…

February 25, 2021
Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs
Letter / Comment
TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and by lowering cost of its tests for SARS-CoV-2, TB, HIV, HCV, and other diseases…

February 18, 2021
Nitrosamines and TB Medicines Information Note and Patient FAQs
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG has developed several materials to help people affected by TB, advocates, policymakers, and implementers understand how the identification of…

February 16, 2021
Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
Statement / Press
Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.

January 21, 2021
Good COPs or Bad COPs: Promoting Interventions for Co-Infections and Advanced HIV Disease in 2021 PEPFAR Country Operational Plans (COPs)
Webinar / Presentation
On January 21, 2021, Treatment Action Group (TAG), Health GAP, and MSF Access Campaign presented this webinar on how to engage in PEPFAR COPs advocacy and promote the prioritization of interventions that address co-infections and advanced HIV disease.

December 11, 2020
2020 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

December 7, 2020
2020 Report on TB Research Funding Trends
TB R&D Report
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.

November 11, 2020
TAGline November 2020
‘The Struggle of a Lifetime’ (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before…

Back To Top